Patient subgroup restrictions varied widely across health plans, which could create access challenges for patients within approved populations for orphan and FDA-expedited drugs, researchers said.
Patient subgroup restrictions varied widely across health plans, which could create access challenges for patients within approved populations for orphan and FDA-expedited drugs, researchers said.
Patient subgroup restrictions...